Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
POTEF antisense RNA 1 (POTEF-AS1) is a long non-coding RNA (lncRNA) located on chromosome 2q21.1, as annotated by the HUGO Gene Nomenclature Committee[5]. It is a natural antisense transcript to the POTEF gene, meaning it is transcribed from the DNA strand opposite the protein-coding POTEF (POTE ankyrin domain family member F) gene[1][5]. Like other antisense lncRNAs, POTEF-AS1 likely exerts its biological effects through mechanisms such as modulating the expression, stability, or post-transcriptional processing of its sense counterpart gene[3][6]. Although there are no published data specifically describing POTEF-AS1 as a direct therapeutic target or listing interacting drugs, related antisense lncRNAs are known to play context-dependent roles in cancer, including tumor progression or suppression, via interactions with transcription factors, epigenetic regulators, or RNA-binding proteins[3][6]. The specific biological and disease roles of POTEF-AS1 remain poorly characterized in the current literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on POTEF antisense RNA 1 (POTEF-AS1).